New imaging test could spot rare childhood disease sooner

NCT ID NCT04943211

Recruiting now Diagnosis Sponsor: Anna Raciborska Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to improve how doctors diagnose and monitor histiocytosis, a rare disease that causes abnormal cell growth, in children under 18. Researchers will use a special imaging agent called fluorodeoxyglucose (18F-FDG) in PET-CT scans, along with genetic testing of tumor tissue and blood. The goal is to see how well these methods track the disease over time, potentially leading to earlier detection and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fluorodeoxyglucose (18F-FDG)
What this could lead to: If successful, this could lead to better, earlier detection of histiocytosis in children and more precise monitoring of the disease.
What could go wrong: This is a single-center, early-phase trial focused on imaging, not treatment. The results may not apply broadly, and the imaging agent carries standard radiation risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HISTIOCYTOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

histiocytosis Histiocytosis, Langerhans-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HISTIOCYTOSIS

Contacts and locations

Locations

Mother and Child Institute
RECRUITING

Warsaw, Mazovian, 01-211, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.